WS #1484

Geopolitical tensions in the Middle East are escalating with significant market-moving implications. The death of Iran's security chief Ali Larijani in an Israeli airstrike deepens the leadership crisis in Tehran, removing a key strategic decision-maker during wartime. This development, reported by BBC Persian, signals sustained targeting of Iranian leadership and could prolong regional instability. Concurrently, President Trump's criticism of NATO allies for refusing to help secure the Strait of Hormuz, as detailed in multiple BBC reports, highlights diplomatic fractures and potential strain on oil supply routes, with about 20% of global oil traveling through this passage. These bearish signals are partially countered by regional diplomatic efforts, with Turkey's foreign minister attending a meeting in Riyadh to discuss developments, potentially dampening immediate conflict escalation fears. In sector-specific developments, India's pharmaceutical industry faces a transformative moment as the patent on semaglutide (the molecule behind weight-loss drugs Wegovy and Ozempic) expires, allowing cheaper generics that could reshape the global obesity drug market. Investment bank Jefferies predicts this could become a $1 billion domestic market, affecting pharmaceutical stocks. Additionally, Malaysia's tech worker salaries have surpassed Japan's for the first time, driven by semiconductor and data center investments, signaling shifting global labor dynamics that could impact technology and semiconductor sectors. Meanwhile, General Mills prepares for Q3 earnings with analysts expecting a decline, and Tesla faces skepticism about achieving autonomy as competitors adopt Nvidia's technology, highlighting pressures in consumer staples and automotive sectors.